CARsgen Therapeutics Holdings Limited (HKG:2171)
Hong Kong · Delayed Price · Currency is HKD 10.87
-1.09 (-9.11%)
At close: Mar 6, 2026
HKG:2171 Revenue
In the year 2025, CARsgen Therapeutics Holdings had annual revenue of 125.66M CNY with 218.74% growth. CARsgen Therapeutics Holdings had revenue of 50.96M in the half year ending June 30, 2025.
Revenue
125.66M CNY
Revenue Growth
+218.74%
P/S Ratio
43.20
Revenue / Employee
338.71K CNY
Employees
371
Market Cap
6.04B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.66M | 86.24M | 218.74% |
| Dec 31, 2024 | 39.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 25.81M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.49B |
| Shanghai Haohai Biological Technology | 2.75B |
| HBM Holdings | 908.35M |
| Alphamab Oncology | 861.24M |
| Lepu Biopharma | 767.54M |
| Abbisko Cayman | 678.11M |
| Ocumension Therapeutics | 595.79M |
| CStone Pharmaceuticals | 221.89M |